The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

May 1, 2024 · Exelixis (NASDAQ:EXEL) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ...

$32.53
OFF

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

2 weeks from now

Dec 17, 2024 · Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and a low estimate of $27.00.

nasdaq.com

$330
OFF

The Analyst Verdict: Boston Beer Co In The Eyes Of 5 Experts

2 weeks from now

6 hours ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $330.4, a high estimate of $389.00, and a low estimate of $290.00.

nasdaq.com

93%
OFF

The Analyst Verdict: NOV In The Eyes Of 9 Experts | Nasdaq

2 weeks from now

10 hours ago · The Analyst Verdict: NOV In The Eyes Of 9 Experts January 15, 2025 — 01:00 pm EST ... With a net margin of 5.93%, the company demonstrates strong profitability and …

nasdaq.com

$470.25
OFF

The Analyst Verdict: Bio-Rad Laboratories In The Eyes Of 4 Experts

2 weeks from now

1 day ago · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $470.25, along with a high estimate of $481.00 and a low …

benzinga.com

$26
OFF

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

2 weeks from now

Analysts have set 12-month price targets for Exelixis, revealing an average target of $26.4, a high estimate of $28.00, and a low estimate of $25.00. This upward trend is evident, with the …

capedge.com

$216
OFF

The Analyst Verdict: Fabrinet In The Eyes Of 5 Experts

2 weeks from now

May 1, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $216.4, a high estimate of $230.00, and a low estimate of $200.00.

businessinsider.com

$52.57
OFF

The Analyst Verdict: DraftKings In The Eyes Of 14 Experts

2 weeks from now

Jan 7, 2025 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $52.57, a high estimate of $62.00, and a low estimate of $44.00.

nasdaq.com

$94.42
OFF

The Analyst Verdict: Enphase Energy In The Eyes Of 33 Experts

2 weeks from now

2 days ago · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $94.42, a high estimate of $145.00, and a low estimate of $61.00.

benzinga.com

$175.11
OFF

The Analyst Verdict: Blackstone In The Eyes Of 19 Experts

2 weeks from now

2 days ago · In the assessment of 12-month price targets, analysts unveil insights for Blackstone, presenting an average target of $175.11, a high estimate of $230.00, and a low estimate of …

nasdaq.com

$4
OFF

The Analyst Verdict: Rigetti Computing In The Eyes Of 5 Experts

2 weeks from now

Dec 20, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.8, along with a high estimate of $12.00 and a low estimate …

nasdaq.com

FAQs about The Analyst Verdict: Exelixis In The Eyes Of 5 Experts Coupon?

How much does Exelixis cost?

Analysts have set 12-month price targets for Exelixis, revealing an average target of $26.4, a high estimate of $28.00, and a low estimate of $25.00. This upward trend is evident, with the current average reflecting a 6.67% increase from the previous average price target of $24.75. ...

What do analysts do about Exelixis?

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company. ...

Why did Exelixis perform well in the 3 months period?

This could be attributed to factors such as growth expectations or operational capacity. Revenue Growth: Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of 13.15% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. ...

What is Exelixis used for?

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. ...